{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:51:46Z","timestamp":1778781106130,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00134-019-05819-3","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T22:51:43Z","timestamp":1572475903000},"page":"1703-1717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":167,"title":["Epidemiology of intra-abdominal infection and sepsis in critically ill patients: \u201cAbSeS\u201d, a multinational observational cohort study and ESICM Trials Group Project"],"prefix":"10.1007","volume":"45","author":[{"name":"the Abdominal Sepsis Study (AbSeS) group on behalf of the Trials Group of the European Society of Intensive Care Medicine","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2145-0345","authenticated-orcid":false,"given":"Stijn","family":"Blot","sequence":"first","affiliation":[]},{"given":"Massimo","family":"Antonelli","sequence":"additional","affiliation":[]},{"given":"Kostoula","family":"Arvaniti","sequence":"additional","affiliation":[]},{"given":"Koen","family":"Blot","sequence":"additional","affiliation":[]},{"given":"Ben","family":"Creagh-Brown","sequence":"additional","affiliation":[]},{"given":"Dylan","family":"de Lange","sequence":"additional","affiliation":[]},{"given":"Jan","family":"De Waele","sequence":"additional","affiliation":[]},{"given":"Mieke","family":"Deschepper","sequence":"additional","affiliation":[]},{"given":"Yalim","family":"Dikmen","sequence":"additional","affiliation":[]},{"given":"George","family":"Dimopoulos","sequence":"additional","affiliation":[]},{"given":"Christian","family":"Eckmann","sequence":"additional","affiliation":[]},{"given":"Guy","family":"Francois","sequence":"additional","affiliation":[]},{"given":"Massimo","family":"Girardis","sequence":"additional","affiliation":[]},{"given":"Despoina","family":"Koulenti","sequence":"additional","affiliation":[]},{"given":"Sonia","family":"Labeau","sequence":"additional","affiliation":[]},{"given":"Jeffrey","family":"Lipman","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Lipovestky","sequence":"additional","affiliation":[]},{"given":"Emilio","family":"Maseda","sequence":"additional","affiliation":[]},{"given":"Philippe","family":"Montravers","sequence":"additional","affiliation":[]},{"given":"Adam","family":"Mikstacki","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9-Artur","family":"Paiva","sequence":"additional","affiliation":[]},{"given":"Cecilia","family":"Pereyra","sequence":"additional","affiliation":[]},{"given":"Jordi","family":"Rello","sequence":"additional","affiliation":[]},{"given":"Jean-Francois","family":"Timsit","sequence":"additional","affiliation":[]},{"given":"Dirk","family":"Vogelaers","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"key":"5819_CR1","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1001\/jama.2009.1754","volume":"302","author":"JL Vincent","year":"2009","unstructured":"Vincent JL, Rello J, Marshall J et al (2009) International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323\u20132329. \nhttps:\/\/doi.org\/10.1001\/jama.2009.1754","journal-title":"JAMA"},{"key":"5819_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.5603\/AIT.2015.0047","volume":"47","author":"A K\u00fcbler","year":"2015","unstructured":"K\u00fcbler A, Adamik B, Ciszewicz-Adamiczka B, Ostrowska E (2015) Severe sepsis in intensive care units in Poland\u2014a point prevalence study in 2012 and 2013. Anaesthesiol Intensive Ther 47:315\u2013319. \nhttps:\/\/doi.org\/10.5603\/AIT.2015.0047","journal-title":"Anaesthesiol Intensive Ther"},{"key":"5819_CR3","doi-asserted-by":"publisher","first-page":"ofy313","DOI":"10.1093\/ofid\/ofy313","volume":"5","author":"Y Sakr","year":"2018","unstructured":"Sakr Y, Jaschinski U, Wittebole X et al (2018) Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit. Open Forum Infect Dis 5:ofy313. \nhttps:\/\/doi.org\/10.1093\/ofid\/ofy313","journal-title":"Open Forum Infect Dis"},{"key":"5819_CR4","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2165\/00003495-200565120-00002","volume":"65","author":"S Blot","year":"2005","unstructured":"Blot S, De Waele JJ (2005) Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 65:1611\u20131620","journal-title":"Drugs"},{"key":"5819_CR5","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s00134-016-4307-6","volume":"42","author":"P Montravers","year":"2016","unstructured":"Montravers P, Blot S, Dimopoulos G et al (2016) Therapeutic management of peritonitis: a comprehensive guide for intensivists. Intensive Care Med 42:1234\u20131247. \nhttps:\/\/doi.org\/10.1007\/s00134-016-4307-6","journal-title":"Intensive Care Med"},{"key":"5819_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/sur.2009.9930","volume":"11","author":"JS Solomkin","year":"2010","unstructured":"Solomkin JS, Mazuski JE, Bradley JS et al (2010) Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt) 11:79\u2013109. \nhttps:\/\/doi.org\/10.1089\/sur.2009.9930","journal-title":"Surg Infect (Larchmt)"},{"key":"5819_CR7","doi-asserted-by":"publisher","first-page":"R87","DOI":"10.1186\/cc13854","volume":"18","author":"T Azuhata","year":"2014","unstructured":"Azuhata T, Kinoshita K, Kawano D et al (2014) Time from admission to initiation of surgery for source control is a critical determinant of survival in patients with gastrointestinal perforation with associated septic shock. Crit Care 18:R87. \nhttps:\/\/doi.org\/10.1186\/cc13854","journal-title":"Crit Care"},{"key":"5819_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13017-017-0141-6","volume":"12","author":"M Sartelli","year":"2017","unstructured":"Sartelli M, Chichom-Mefire A, Labricciosa FM et al (2017) The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg 12:29. \nhttps:\/\/doi.org\/10.1186\/s13017-017-0141-6","journal-title":"World J Emerg Surg"},{"key":"5819_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13017-018-0177-2","volume":"13","author":"M Tolonen","year":"2018","unstructured":"Tolonen M, Coccolini F, Ansaloni L et al (2018) Getting the invite list right: a discussion of sepsis severity scoring systems in severe complicated intra-abdominal sepsis and randomized trial inclusion criteria. World J Emerg Surg 13:17. \nhttps:\/\/doi.org\/10.1186\/s13017-018-0177-2","journal-title":"World J Emerg Surg"},{"key":"5819_CR10","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.2165\/11599800-000000000-00000","volume":"72","author":"S Blot","year":"2012","unstructured":"Blot S, De Waele JJ, Vogelaers D (2012) Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs 72:e17\u2013e32. \nhttps:\/\/doi.org\/10.2165\/11599800-000000000-00000","journal-title":"Drugs"},{"issue":"7","key":"5819_CR11","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1097\/01.CCM.0000168253.91200.83","volume":"33","author":"Thierry Calandra","year":"2005","unstructured":"Calandra T, Cohen J (2005) International Sepsis Forum Definition of Infection in the ICU Consensus Conference The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 33:1538\u20131548. \nhttps:\/\/doi.org\/10.1097\/01.ccm.0000168253.91200.83","journal-title":"Critical Care Medicine"},{"key":"5819_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1164\/ajrccm.157.2.9705064","volume":"157","author":"JL Trouillet","year":"1998","unstructured":"Trouillet JL, Chastre J, Vuagnat A et al (1998) Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157:531\u2013539. \nhttps:\/\/doi.org\/10.1164\/ajrccm.157.2.9705064","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"5819_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"Mervyn Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315(8):801\u2013810. \nhttps:\/\/doi.org\/10.1001\/jama.2016.0287","journal-title":"JAMA"},{"key":"5819_CR14","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0, 2015. \nhttp:\/\/www.eucast.org\n\n. Accessed 31 Mar 2014"},{"key":"5819_CR15","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/cid\/ciy378","volume":"67","author":"SS Kadri","year":"2018","unstructured":"Kadri SS, Adjemian J, Lai YL et al (2018) Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis 67:1803\u20131814. \nhttps:\/\/doi.org\/10.1093\/cid\/ciy378","journal-title":"Clin Infect Dis"},{"key":"5819_CR16","doi-asserted-by":"publisher","first-page":"ofz110","DOI":"10.1093\/ofid\/ofz110","volume":"6","author":"SS Kadri","year":"2019","unstructured":"Kadri SS, Lai YLE, Ricotta EE et al (2019) External validation of difficult-to-treat resistance prevalence and mortality risk in gram-negative bloodstream infection using electronic health record data from 140 US hospitals. Open Forum Infect Dis 6:ofz110. \nhttps:\/\/doi.org\/10.1093\/ofid\/ofz110","journal-title":"Open Forum Infect Dis"},{"key":"5819_CR17","doi-asserted-by":"publisher","first-page":"e619","DOI":"10.1016\/S2214-109X(18)30186-4","volume":"6","author":"A Versporten","year":"2018","unstructured":"Versporten A, Zarb P, Caniaux I et al (2018) Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. Lancet Glob Health 6:e619\u2013e629. \nhttps:\/\/doi.org\/10.1016\/S2214-109X(18)30186-4","journal-title":"Lancet Glob Health"},{"key":"5819_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ijantimicag.2009.11.015","volume":"35","author":"D Vogelaers","year":"2010","unstructured":"Vogelaers D, De Bels D, For\u00eat F et al (2010) Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates\u2014a multicentre, observational survey in critically ill patients. Int J Antimicrob Agents 35:375\u2013381. \nhttps:\/\/doi.org\/10.1016\/j.ijantimicag.2009.11.015","journal-title":"Int J Antimicrob Agents"},{"key":"5819_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/01.SLA.0000048551.32606.73","volume":"237","author":"JS Solomkin","year":"2003","unstructured":"Solomkin JS, Yellin AE, Rotstein OD et al (2003) Ertapenem versus piperacillin\/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 237:235\u2013245. \nhttps:\/\/doi.org\/10.1097\/01.SLA.0000048551.32606.73","journal-title":"Ann Surg"},{"key":"5819_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00000658-200101000-00013","volume":"233","author":"JS Solomkin","year":"2001","unstructured":"Solomkin JS, Wilson SE, Christou NV et al (2001) Results of a clinical trial of clinafloxacin versus imipenem\/cilastatin for intraabdominal infections. Ann Surg 233:79\u201387. \nhttps:\/\/doi.org\/10.1097\/00000658-200101000-00013","journal-title":"Ann Surg"},{"key":"5819_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/00000658-199603000-00012","volume":"223","author":"JS Solomkin","year":"1996","unstructured":"Solomkin JS, Reinhart HH, Dellinger EP et al (1996) Results of a randomized trial comparing sequential intravenous\/oral treatment with ciprofloxacin plus metronidazole to imipenem\/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 223:303\u2013315. \nhttps:\/\/doi.org\/10.1097\/00000658-199603000-00012","journal-title":"Ann Surg"},{"key":"5819_CR22","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s15010-009-8249-6","volume":"37","author":"J de Ruiter","year":"2009","unstructured":"de Ruiter J, Weel J, Manusama E et al (2009) The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis. Infection 37:522\u2013527. \nhttps:\/\/doi.org\/10.1007\/s15010-009-8249-6","journal-title":"Infection"},{"key":"5819_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1017\/ice.2019.59","volume":"40","author":"K Blot","year":"2019","unstructured":"Blot K, Hammami N, Blot S et al (2019) Increasing burden of Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecium in hospital-acquired bloodstream infections (2000\u20132014): a national dynamic cohort study. Infect Control Hosp Epidemiol 40:705\u2013709. \nhttps:\/\/doi.org\/10.1017\/ice.2019.59","journal-title":"Infect Control Hosp Epidemiol"},{"key":"5819_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/CCM.0000000000002011","volume":"45","author":"ML Mart\u00ednez","year":"2017","unstructured":"Mart\u00ednez ML, Ferrer R, Torrents E et al (2017) Impact of source control in patients with severe sepsis and septic shock. Crit Care Med 45:11\u201319. \nhttps:\/\/doi.org\/10.1097\/CCM.0000000000002011","journal-title":"Crit Care Med"},{"key":"5819_CR25","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1097\/01.CCM.0000201889.39443.D2","volume":"34","author":"P Montravers","year":"2006","unstructured":"Montravers P, Dupont H, Gauzit R et al (2006) Candida as a risk factor for mortality in peritonitis. Crit Care Med 34:646\u2013652. \nhttps:\/\/doi.org\/10.1097\/01.CCM.0000201889.39443.D2","journal-title":"Crit Care Med"},{"key":"5819_CR26","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/cid\/civ707","volume":"61","author":"W Knitsch","year":"2015","unstructured":"Knitsch W, Vincent JL, Utzolino S et al (2015) A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections. Clin Infect Dis 61:1671\u20131678. \nhttps:\/\/doi.org\/10.1093\/cid\/civ707","journal-title":"Clin Infect Dis"},{"key":"5819_CR27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jcrc.2019.02.029","volume":"52","author":"K van de Groep","year":"2019","unstructured":"van de Groep K, Verhoeff TL, Verboom DM et al (2019) Epidemiology and outcomes of source control procedures in critically ill patients with intra-abdominal infection. J Crit Care 52:258\u2013264. \nhttps:\/\/doi.org\/10.1016\/j.jcrc.2019.02.029","journal-title":"J Crit Care"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-019-05819-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00134-019-05819-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-019-05819-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:05:44Z","timestamp":1603843544000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00134-019-05819-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5819"],"URL":"https:\/\/doi.org\/10.1007\/s00134-019-05819-3","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,29]]},"assertion":[{"value":"28 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Received grants related to the submitted work: S. Blot (Pfizer). Received honoraria or grants outside the submitted work: M. Antonelli (Fresenius, Pfizer, Toray); J. De Waele (Research Foundation Flanders, Pfizer, Bayer, MSD); C. Eckmann (Merck, Pfizer); J. Lipman (MSD, Pfizer); E. Maseda (Astellas Pharma, Pfizer, MSD); All other authors: no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}